Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira

The approval of Humira biosimilar is the fourth U.S. approval of a biosimilar product for Pfizer (PFE) in 2019.

Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex

Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.

How Pfizer (PFE) Stock Stands Out in a Strong Industry

Pfizer (PFE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Stock Market News for Nov 18, 2019

Benchmarks closed at record highs on Friday on U.S.-China trade deal hopes in spite of mixed economic data.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

Kinjel Shah headshot

4 Big Drugmakers to Bet on After a Great Earnings Season

Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study

Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.

Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed

Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.

Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss

Mylan's (MYL) earnings beat estimates but sales miss the same in the third quarter of 2019. The company updates guidance for 2019.

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.

Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales

Exelixis (EXEL) reports solid third-quarter 2019 results as Cabometyx maintains momentum.

Bristol-Myers' (BMY) Q3 Earnings & Revenues Beat Estimates

Bristol-Myers (BMY) beats both earnings and sales estimates in the third quarter, primarily on robust sales of Eliquis and Sprycel.

Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View

Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.

Stock Market News For Oct 30, 2019

Benchmarks closed in the negative territory on Tuesday due to Alphabet???s weak earnings report and uncertainties in timely completion of U.S-China Phase one deal.

Sweta Killa headshot

Healthcare ETFs Win in October: Here's Why

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

Strong Q3 Earnings Data Deluge

Strong Q3 Earnings Data Deluge

Mark Vickery headshot

Q3 Earnings Bonanza: GM, MRK, MA & More

GM fought through strike headwinds to beat estimates, Merck's cancer drug performs great, and Pfizer and Mastercard beat, too.

Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View

Pfizer (PFE) beats estimates for third-quarter earnings and sales and raises earnings guidance range for 2019 while tightening revenue outlook.

Pfizer (PFE) Beats Q3 Earnings and Revenue Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 19.05% and 4.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.

David Borun headshot

Positive Earnings Results Push Equities to All-Time Highs

A slew of positive results buoys stocks as we head toward the October Fed meeting

Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q3 sales, genericization of some older drugs are likely to have hurt the same.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $36.45, marking a -0.03% move from the previous day.

Sweta Killa headshot

What's in Store for Healthcare ETFs in Q3 Earnings?

With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.